IMMUNOVANT, INC. Other Comprehensive Income (Loss), Net of Tax
IMMUNOVANT, INC. (IMVT) reported Other Comprehensive Income (Loss), Net of Tax of $1.06 million for the 12-month period ending 2024-03-31, per its 10-K filed 2024-05-29.
Discontinued › Income Statement
us-gaap:OtherComprehensiveIncomeLossNetOfTax · last filed 2024-05-29
- IMMUNOVANT, INC. other comprehensive income (loss), net of tax for the quarter ending 2024-03-31 was $2.51M.
- IMMUNOVANT, INC. other comprehensive income (loss), net of tax for the quarter ending 2023-12-31 was -$1.11M, a 142.48% decline year-over-year.
- IMMUNOVANT, INC. other comprehensive income (loss), net of tax for the quarter ending 2023-09-30 was $69.00K.
- IMMUNOVANT, INC. other comprehensive income (loss), net of tax for the quarter ending 2023-06-30 was $270.00K.
- IMMUNOVANT, INC. other comprehensive income (loss), net of tax for fiscal 2024 was $1.06M, a 135.71% increase from fiscal 2023.
- IMMUNOVANT, INC. other comprehensive income (loss), net of tax for fiscal 2023 was $448.00K, a 36.18% decline from fiscal 2022.
- IMMUNOVANT, INC. other comprehensive income (loss), net of tax for fiscal 2022 was $702.00K.
- IMMUNOVANT, INC. other comprehensive income (loss), net of tax for fiscal 2021 was -$282.00K.
| Period end | Other Comprehensive Income (Loss), Net of Tax 3 month | Other Comprehensive Income (Loss), Net of Tax 3 month as first filed | Other Comprehensive Income (Loss), Net of Tax 6 month | Other Comprehensive Income (Loss), Net of Tax 9 month | Other Comprehensive Income (Loss), Net of Tax 12 month |
|---|---|---|---|---|---|
| 2024-03-31 | $2.51M derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-29 | $1.40M derived: sum of 2 quarters · filed 2024-05-29 | $1.46M derived: sum of 3 quarters · filed 2024-05-29 | $1.06M 10-K · filed 2024-05-29 | |
| 2023-12-31 | -$1.11M 10-Q · filed 2024-02-12 | -$1.04M derived: sum of 2 quarters · filed 2024-02-12 | -$1.45M 10-Q · filed 2024-02-12 | -$1.30M derived: sum of 4 quarters · filed 2024-05-29 | |
| 2023-09-30 | $69.00K 10-Q · filed 2023-11-09 | $339.00K 10-Q · filed 2023-11-09 | -$192.00K derived: sum of 3 quarters · filed 2024-05-29 | $2.43M derived: sum of 4 quarters · filed 2024-05-29 | |
| 2023-06-30 | $270.00K 10-Q · filed 2023-08-10 | -$261.00K derived: sum of 2 quarters · filed 2024-05-29 | $2.36M derived: sum of 3 quarters · filed 2024-05-29 | $1.39M derived: sum of 4 quarters · filed 2024-05-29 | |
| 2023-03-31 | -$531.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-05-29 | $2.09M derived: sum of 2 quarters · filed 2024-05-29 | $1.11M derived: sum of 3 quarters · filed 2024-05-29 | $448.00K 10-K · filed 2024-05-29 | |
| 2022-12-31 | $2.62M 10-Q · filed 2024-02-12 | $1.65M derived: sum of 2 quarters · filed 2024-02-12 | $979.00K 10-Q · filed 2024-02-12 | $964.00K derived: sum of 4 quarters · filed 2024-02-12 | |
| 2022-09-30 | -$974.00K 10-Q · filed 2023-11-09 | -$1.64M 10-Q · filed 2023-11-09 | -$1.66M derived: sum of 3 quarters · filed 2023-11-09 | -$1.68M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | -$667.00K 10-Q · filed 2023-08-10 | -$682.00K derived: sum of 2 quarters · filed 2023-08-10 | -$705.00K derived: sum of 3 quarters · filed 2023-08-10 | -$536.00K derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | -$15.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-05-22 | -$38.00K derived: sum of 2 quarters · filed 2023-05-22 | $131.00K derived: sum of 3 quarters · filed 2023-05-22 | $702.00K 10-K · filed 2023-05-22 | |
| 2021-12-31 | -$23.00K 10-Q · filed 2023-02-03 | $146.00K derived: sum of 2 quarters · filed 2023-02-03 | $717.00K 10-Q · filed 2023-02-03 | -$48.00K derived: sum of 4 quarters · filed 2023-02-03 | |
| 2021-09-30 | $169.00K 10-Q · filed 2022-11-04 | $740.00K 10-Q · filed 2022-11-04 | -$25.00K derived: sum of 3 quarters · filed 2022-11-04 | $664.00K derived: sum of 4 quarters · filed 2022-11-04 | |
| 2021-06-30 | $571.00K 10-Q · filed 2022-08-05 | -$194.00K derived: sum of 2 quarters · filed 2022-08-05 | $495.00K derived: sum of 3 quarters · filed 2022-08-05 | $263.00K derived: sum of 4 quarters · filed 2022-08-05 | |
| 2021-03-31 | -$765.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-08 | -$76.00K derived: sum of 2 quarters · filed 2022-06-08 | -$308.00K derived: sum of 3 quarters · filed 2022-06-08 | -$282.00K 10-K · filed 2022-06-08 | |
| 2020-12-31 | $689.00K 10-Q · filed 2022-02-04 | $457.00K derived: sum of 2 quarters · filed 2022-02-04 | $483.00K 10-Q · filed 2022-02-04 | $614.00K derived: sum of 4 quarters · filed 2022-02-04 | |
| 2020-09-30 | -$232.00K 10-Q · filed 2021-11-05 | -$206.00K 10-Q · filed 2021-11-05 | -$75.00K derived: sum of 3 quarters · filed 2021-11-05 | -$224.00K derived: sum of 4 quarters · filed 2021-11-05 | |
| 2020-06-30 | $26.00K 10-Q · filed 2021-08-09 | $157.00K derived: sum of 2 quarters · filed 2021-08-09 | $8.00K derived: sum of 3 quarters · filed 2021-08-09 | -$45.00K derived: sum of 4 quarters · filed 2021-08-09 | |
| 2020-03-31 | $131.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-01 | -$18.00K derived: sum of 2 quarters · filed 2021-06-01 | -$71.00K derived: sum of 3 quarters · filed 2021-06-01 | -$362.00K 10-K · filed 2021-06-01 | |
| 2019-12-31 | -$149.00K 10-Q · filed 2021-02-16 | -$148.00K 10-Q · filed 2020-02-14 | -$202.00K derived: sum of 2 quarters · filed 2021-02-16 | -$493.00K 10-Q · filed 2021-02-16 | -$387.00K derived: sum of 4 quarters · filed 2021-02-16 |
| 2019-09-30 | -$53.00K 10-Q · filed 2020-11-12 | -$344.00K 10-Q · filed 2020-11-12 | -$238.00K derived: sum of 3 quarters · filed 2020-11-12 | -$300.00K derived: sum of 4 quarters · filed 2020-11-12 | |
| 2019-06-30 | -$291.00K 10-Q · filed 2020-08-12 | -$185.00K derived: sum of 2 quarters · filed 2020-08-12 | -$247.00K derived: sum of 3 quarters · filed 2020-08-12 | ||
| 2019-03-31 | $106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-29 | $44.00K derived: sum of 2 quarters · filed 2020-06-29 | $185.00K 10-K · filed 2020-06-29 | ||
| 2018-12-31 | -$62.00K 10-Q · filed 2020-02-14 | $79.00K 10-Q · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |